Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Core Insights - Capricor Therapeutics is participating in one-on-one investor meetings and providing a corporate update at Leerink's Global Healthcare Conference 2025 from March 10-12, 2025 [1][2] - The company will present updates on its lead program, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD) along with other scientific and corporate updates [2] Company Overview - Capricor Therapeutics, Inc. is focused on developing cell and exosome-based therapeutics aimed at treating rare diseases, with deramiocel being its lead product candidate [3] - Deramiocel is an allogeneic cardiac-derived cell therapy that has shown immunomodulatory, antifibrotic, and regenerative actions, specifically for dystrophinopathies and heart disease [3] - The company is also utilizing its proprietary StealthX™ platform for preclinical development in areas such as vaccinology and targeted delivery of therapeutics [3] Commercialization Agreement - Capricor has entered into an exclusive commercialization and distribution agreement for deramiocel in the United States and Japan with Nippon Shinyaku Co., Ltd., pending regulatory approval [5][6]